INVESTIGATOR LOGIN

Login:
Password:
Contact Information

For more information, please contact Quintiles on behalf of Boehringer Ingelheim GmbH:

info@gloria-af.com

See 'Contact Us' link below for phone numbers by country.

GLORIA™-AF stands for "Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation."

The GLORIA™-AF Registry Program is a large, international, prospective registry progam designed to characterize newly diagnosed patients with non-valvular atrial fibrillation at risk for stroke in different regions of the world.

focusOnFocus on
Latest news about the GLORIA™-AF registry will be posted here.

Information regarding the design and rationale of GLORIA™-AF has been published.

Reference: Huisman, M.V. et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167:329-34.

This international website is dedicated to investigators and study staff of the GLORIA™-AF Registry Program as well as the general public including physicians, patients and media. On this website you will find helpful information about the GLORIA™-AF Registry, including the login access to the GLORIA™-AF Electronic Data Capture System for participating investigators. In addition, the latest registry news, disease information, publications and useful links for medical staff and patients can be found here.